PhoreMost demonstrates new approach to rationalise molecular glue drug discovery News - 22nd July 2025
PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics News - 7th May 2025
PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes News - 10th September 2024